Sisse Helle Njor

HrHPV testing vs liquid-based cytology in cervical cancer screening among women aged 50 and older: A prospective study

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Standard

HrHPV testing vs liquid-based cytology in cervical cancer screening among women aged 50 and older : A prospective study. / Andersen, Berit; Njor, Sisse Helle; Jensen, Anne Marie Schak; Johansen, Tonje; Jeppesen, Ulla; Svanholm, Hans.

I: International Journal of Gynecological Cancer, Bind 30, Nr. 11, 11.2020, s. 1678-1683.

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Harvard

Andersen, B, Njor, SH, Jensen, AMS, Johansen, T, Jeppesen, U & Svanholm, H 2020, 'HrHPV testing vs liquid-based cytology in cervical cancer screening among women aged 50 and older: A prospective study', International Journal of Gynecological Cancer, bind 30, nr. 11, s. 1678-1683. https://doi.org/10.1136/ijgc-2020-001457

APA

Andersen, B., Njor, S. H., Jensen, A. M. S., Johansen, T., Jeppesen, U., & Svanholm, H. (2020). HrHPV testing vs liquid-based cytology in cervical cancer screening among women aged 50 and older: A prospective study. International Journal of Gynecological Cancer, 30(11), 1678-1683. https://doi.org/10.1136/ijgc-2020-001457

CBE

Andersen B, Njor SH, Jensen AMS, Johansen T, Jeppesen U, Svanholm H. 2020. HrHPV testing vs liquid-based cytology in cervical cancer screening among women aged 50 and older: A prospective study. International Journal of Gynecological Cancer. 30(11):1678-1683. https://doi.org/10.1136/ijgc-2020-001457

MLA

Vancouver

Andersen B, Njor SH, Jensen AMS, Johansen T, Jeppesen U, Svanholm H. HrHPV testing vs liquid-based cytology in cervical cancer screening among women aged 50 and older: A prospective study. International Journal of Gynecological Cancer. 2020 nov;30(11):1678-1683. https://doi.org/10.1136/ijgc-2020-001457

Author

Andersen, Berit ; Njor, Sisse Helle ; Jensen, Anne Marie Schak ; Johansen, Tonje ; Jeppesen, Ulla ; Svanholm, Hans. / HrHPV testing vs liquid-based cytology in cervical cancer screening among women aged 50 and older : A prospective study. I: International Journal of Gynecological Cancer. 2020 ; Bind 30, Nr. 11. s. 1678-1683.

Bibtex

@article{0498fe8656bd472ba019e2785e4086e9,
title = "HrHPV testing vs liquid-based cytology in cervical cancer screening among women aged 50 and older: A prospective study",
abstract = "Introduction Evidence supports high-risk human papilloma virus (HPV) testing as the primary cervical cancer screening tool. However, benefits and harms should be carefully considered before replacing liquid-based cytology. In women age 50 and older, we evaluated how a commercially available DNA amplification HPV test compares with routine liquid-based cytology. Methods This prospective study included 4043 patients who had a cervical sample analyzed from September 2011 to September 2012. Patients were followed between 64 and 76 months (median: 70 months). Samples were analyzed using both liquid-based cytology and the Cobas 4800 HPV DNA test. We calculated the diagnostic efficacy of liquid-based cytology and HPV, with or without the opposite test as triage, using cervical intraepithelial neoplasia (CIN2+/CIN3+) as reference. Results The patients had a median age of 58 years, (range; 50-90). At baseline, HPV prevalence was 8.0%: A total of 3.7% of patients had atypical squamous cells of undetermined significance or worse (ASCUS+). Positive test results were 1.9% for liquid-based cytology with HPV triage and 3.0% for HPV with liquid-based cytology triage. The cumulative incidence of CIN3+ was 1.0% (40/4043). Sensitivities for CIN3+ were: Liquid-based cytology 47.5% (31.5%-63.9%); liquid-based cytology with HPV triage 45.0% (29.3%-61.5%); HPV 90.0% (76.3%-97.2%); and HPV with liquid-based cytology triage 67.5% (50.9%-81.4%). Corresponding specificities were: Liquid-based cytology 96.6% (96.0%-97.2%); liquid-based cytology with HPV triage 98.5% (98.0%-98.8%); HPV 92.8% (92.0%-93.6%); and HPV with liquid-based cytology triage 97.7% (97.2%-98.1%). At baseline, HPV testing overlooked five cases of gynecological cancer other than cervical cancer. Five cervical cancers were detected, two had been overlooked at baseline by liquid-based cytology and two by HPV testing Conclusion HPV screening using DNA amplification is a promising alternative to liquid-based cytology in women age 50 and older, but evaluation of alternative triage methods is warranted. The risk of overlooking cancers needs consideration when replacing liquid-based cytology with HPV testing as a method for primary screening.",
keywords = "cervical cancer",
author = "Berit Andersen and Njor, {Sisse Helle} and Jensen, {Anne Marie Schak} and Tonje Johansen and Ulla Jeppesen and Hans Svanholm",
year = "2020",
month = nov,
doi = "10.1136/ijgc-2020-001457",
language = "English",
volume = "30",
pages = "1678--1683",
journal = "International Journal of Gynecological Cancer",
issn = "1048-891X",
publisher = "Lippincott Williams & Wilkins, Ltd.",
number = "11",

}

RIS

TY - JOUR

T1 - HrHPV testing vs liquid-based cytology in cervical cancer screening among women aged 50 and older

T2 - A prospective study

AU - Andersen, Berit

AU - Njor, Sisse Helle

AU - Jensen, Anne Marie Schak

AU - Johansen, Tonje

AU - Jeppesen, Ulla

AU - Svanholm, Hans

PY - 2020/11

Y1 - 2020/11

N2 - Introduction Evidence supports high-risk human papilloma virus (HPV) testing as the primary cervical cancer screening tool. However, benefits and harms should be carefully considered before replacing liquid-based cytology. In women age 50 and older, we evaluated how a commercially available DNA amplification HPV test compares with routine liquid-based cytology. Methods This prospective study included 4043 patients who had a cervical sample analyzed from September 2011 to September 2012. Patients were followed between 64 and 76 months (median: 70 months). Samples were analyzed using both liquid-based cytology and the Cobas 4800 HPV DNA test. We calculated the diagnostic efficacy of liquid-based cytology and HPV, with or without the opposite test as triage, using cervical intraepithelial neoplasia (CIN2+/CIN3+) as reference. Results The patients had a median age of 58 years, (range; 50-90). At baseline, HPV prevalence was 8.0%: A total of 3.7% of patients had atypical squamous cells of undetermined significance or worse (ASCUS+). Positive test results were 1.9% for liquid-based cytology with HPV triage and 3.0% for HPV with liquid-based cytology triage. The cumulative incidence of CIN3+ was 1.0% (40/4043). Sensitivities for CIN3+ were: Liquid-based cytology 47.5% (31.5%-63.9%); liquid-based cytology with HPV triage 45.0% (29.3%-61.5%); HPV 90.0% (76.3%-97.2%); and HPV with liquid-based cytology triage 67.5% (50.9%-81.4%). Corresponding specificities were: Liquid-based cytology 96.6% (96.0%-97.2%); liquid-based cytology with HPV triage 98.5% (98.0%-98.8%); HPV 92.8% (92.0%-93.6%); and HPV with liquid-based cytology triage 97.7% (97.2%-98.1%). At baseline, HPV testing overlooked five cases of gynecological cancer other than cervical cancer. Five cervical cancers were detected, two had been overlooked at baseline by liquid-based cytology and two by HPV testing Conclusion HPV screening using DNA amplification is a promising alternative to liquid-based cytology in women age 50 and older, but evaluation of alternative triage methods is warranted. The risk of overlooking cancers needs consideration when replacing liquid-based cytology with HPV testing as a method for primary screening.

AB - Introduction Evidence supports high-risk human papilloma virus (HPV) testing as the primary cervical cancer screening tool. However, benefits and harms should be carefully considered before replacing liquid-based cytology. In women age 50 and older, we evaluated how a commercially available DNA amplification HPV test compares with routine liquid-based cytology. Methods This prospective study included 4043 patients who had a cervical sample analyzed from September 2011 to September 2012. Patients were followed between 64 and 76 months (median: 70 months). Samples were analyzed using both liquid-based cytology and the Cobas 4800 HPV DNA test. We calculated the diagnostic efficacy of liquid-based cytology and HPV, with or without the opposite test as triage, using cervical intraepithelial neoplasia (CIN2+/CIN3+) as reference. Results The patients had a median age of 58 years, (range; 50-90). At baseline, HPV prevalence was 8.0%: A total of 3.7% of patients had atypical squamous cells of undetermined significance or worse (ASCUS+). Positive test results were 1.9% for liquid-based cytology with HPV triage and 3.0% for HPV with liquid-based cytology triage. The cumulative incidence of CIN3+ was 1.0% (40/4043). Sensitivities for CIN3+ were: Liquid-based cytology 47.5% (31.5%-63.9%); liquid-based cytology with HPV triage 45.0% (29.3%-61.5%); HPV 90.0% (76.3%-97.2%); and HPV with liquid-based cytology triage 67.5% (50.9%-81.4%). Corresponding specificities were: Liquid-based cytology 96.6% (96.0%-97.2%); liquid-based cytology with HPV triage 98.5% (98.0%-98.8%); HPV 92.8% (92.0%-93.6%); and HPV with liquid-based cytology triage 97.7% (97.2%-98.1%). At baseline, HPV testing overlooked five cases of gynecological cancer other than cervical cancer. Five cervical cancers were detected, two had been overlooked at baseline by liquid-based cytology and two by HPV testing Conclusion HPV screening using DNA amplification is a promising alternative to liquid-based cytology in women age 50 and older, but evaluation of alternative triage methods is warranted. The risk of overlooking cancers needs consideration when replacing liquid-based cytology with HPV testing as a method for primary screening.

KW - cervical cancer

UR - http://www.scopus.com/inward/record.url?scp=85095419773&partnerID=8YFLogxK

U2 - 10.1136/ijgc-2020-001457

DO - 10.1136/ijgc-2020-001457

M3 - Journal article

C2 - 33037107

AN - SCOPUS:85095419773

VL - 30

SP - 1678

EP - 1683

JO - International Journal of Gynecological Cancer

JF - International Journal of Gynecological Cancer

SN - 1048-891X

IS - 11

ER -